F001 Future of Dermatology: Dermatology Beyond 2040
DESCRIPTION
This year, the Future of Dermatology Symposium turns its attention to the long horizon. What will the dermatology visit of 2040 look like? Who—or what—will perform the skin exam? How will imaging, artificial intelligence, ambient documentation, and decentralized diagnostics restructure the clinic, the encounter, and the workforce? The session will pair forward-looking lectures with abstract presentations that stress-test these questions against real data and real technology.
We are pleased to feature Allen Halpern, MD, on the next generation of imaging devices entering the clinic room, and Eugene Semenov, MD, MA, on the integration of artificial intelligence into the dermatology office. Their talks will frame the abstract session, in which our expert panel—spanning therapeutics, diagnostics, molecular technologies, AI, telemedicine, imaging, and digital health—will select the most original and consequential submissions for presentation.
This session is not certified for AMA PRA Category 1 CME Credit.
LEARNING OBJECTIVES
Examine how imaging, artificial intelligence, and ambient clinical technologies are likely to reshape the structure of the visit, the role of the dermatologist, and the patient experience over the next 15 years.
Develop a critical framework for distinguishing transformative innovations from incremental ones, with attention to validation, equity, workflow integration, and regulatory readiness.
Through featured lectures and selected abstracts, identify the translational pathways by which current discoveries in imaging, AI, and digital health are moving toward routine clinical use.
SCHEDULE
1:00 PM
Beyond the Dermatoscope, Vectra and RCM...point-of-care derm devices in 2040
Allan C. Halpern, MD, FAAD
1:40 PM
Beyond Open Evidence, ChatGPT and Claude...AI at the bedside
Yevgeniy Semenov, MD, MS, FAAD
2:20 PM
Panel Discussion and Town Hall Q/A
3:00 PM
Abstract Presentations
DIRECTOR
Hensin Tsao, MD, PhD, FAAD
CO-DIRECTORS
Lilit Garibyan, PhD, MD, FAAD
Harvard Medical School & Wellman Center/Mass General Hospital
Allan C. Halpern, MD, FAAD
Memorial Sloan Kettering Cancer Center
Martina J. Porter, MD, FAAD
Bobby Y. Reddy, MD, FAAD
Yevgeniy Semenov, MD, MS, FAAD
Sandy Sharon Tsao, MD, FAAD
DISCLOSURES
Lilit Garibyan, PhD, MD, FAAD
Absci – Consultant (1099 relationship)(Honoraria); Annecy Bio – Board of Directors(Stock); Brixton Biosciences – Consultant(Fees), Stockholder(Stock); Clarity Cosmetics, Inc. – Stockholder Private Company(No Compensation Received); EyeCool – Stockholder(Stock); Matilda Venture Studio – Board of Directors(Stock);
Allan C. Halpern, MD, FAAD
Canfield Scientific, Inc. – Consultant(Other Financial Benefit); SpotDoc – Founder(Other Financial Benefit);
Martina J. Porter, MD, FAAD
AbbVie – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Alumis – Consultant(Fees); AnaptysBio – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Bayer – Investigator(Grants/Research Funding); Beth Israel Deaconess Medical Center – Other(Patent royalties or other compensation for Intellectual Property Rights); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(No Compensation Received); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Consultant(Fees); Merck – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Mirador – Investigator(Grants/Research Funding); Moonlake – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Investigator(Grants/Research Funding); Oasis Pharmaceuticals – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Prometheus Laboratories, Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Trifecta Clinical – Consultant(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Zura Bio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);
Bobby Y. Reddy, MD, FAAD
Pi Health – Employee (w-2 relationship)(Salary);
Yevgeniy Semenov, MD, MS, FAAD
Alterome Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria); Galderma – Advisory Board(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Pyxis Oncology – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria);
Sandy Sharon Tsao, MD, FAAD
Beiersdorf, Inc. – Consultant (1099 relationship)(Honoraria); Epiphany Dermatology – Advisory Board(Stock); WorldCare Clinical LLC – Consultant (1099 relationship)(Honoraria);